http://www.reportlinker.com/report/search/isAdwords//isCountryAdwords//theme/antiviral_therapeutics Wed, 19 Jun 2013 01:59:33 +0000 helpdesk@reportlinker.com Copyright 2013, Reportlinker Zend_Feed en-us http://blogs.law.harvard.edu/tech/rss http://www.reportlinker.com/d014392227/U-S-Antiviral-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014392227/U-S-Antiviral-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Administer as soon as possible after illness onset influenza virus replication and sites for antiviral inhibition de clercq. Nature reviews- drug discovery 5:1015, 2006 approved antiviral drugs ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/d012665090/The-Brazilian-Antiviral-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d012665090/The-Brazilian-Antiviral-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Can inhibit virus replication or treat viral infection (2). For this reason, plant extracts and components are becoming more important as potential sources for antiviral agents. Plant extract ...]]> Mon, 31 Jan 2011 23:00:00 +0000 http://www.reportlinker.com/d014100049/World-Liver-Diseases-Therapeutics-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014100049/World-Liver-Diseases-Therapeutics-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Portfolio and recent developments is also provided in the report. Transparency market research liver diseases therapeutics market - global industry analysis, size, share, trends ...]]> Mon, 31 Dec 2012 23:00:00 +0000 http://www.reportlinker.com/d013219757/Influenza-Sector-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013219757/Influenza-Sector-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Like illness anti-flu therapeutic tcn-032 peak revenue forecast for us and eu5 ($714m base; $1.212B upside) forecast incidence rate base average incidence of influenza during non-epidemic and epidemic ...]]> Thu, 31 May 2012 22:00:00 +0000 http://www.reportlinker.com/d013407987/Influenza-Sector-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013407987/Influenza-Sector-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Influenza-like illness anti-flu therapeutic tcn-032 revenue forecast for us and eu5 ($714m base; $1.212B upside) forecast incidence rate base average incidence of influenza during non ...]]> Sat, 30 Jun 2012 22:00:00 +0000 http://www.reportlinker.com/d013114217/Biological-Therapy-in-China-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013114217/Biological-Therapy-in-China-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Aging resveratrol (red wine) Probiotics Pomegranate juice for pca Nanotechnologies: Nerve regeneration scaffold Nanotubes for bone regenretation antiviral nanoemulsion Creative ...]]> Wed, 29 Feb 2012 23:00:00 +0000 http://www.reportlinker.com/d013775717/U-S-Pharmaceutical-Business.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013775717/U-S-Pharmaceutical-Business.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Discovery of novel anti-hiv antibodies in collaboration with iavi and scripps Recognized as fierce 15 by fiercebiotech 6 influenza promising therapeutic for pandemic and severe seasonal influenza ...]]> Sun, 30 Sep 2012 22:00:00 +0000 http://www.reportlinker.com/d013928387/U-S-Interferon-Sector.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013928387/U-S-Interferon-Sector.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Effectivehealthcare.Ahrq.Gov/hepctreatment.Cfm. Key question 2: this question has two parts: a. What is the comparative effectiveness of antiviral treatments on intermediate outcomes, such as the rate of sustained virologic response or histologic ...]]> Fri, 31 Dec 2010 23:00:00 +0000 http://www.reportlinker.com/d013249721/U-S-Pharmaceutical-Business.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d013249721/U-S-Pharmaceutical-Business.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Study initiated in december 2011 Phase i data expected h2 2012 first-in-class inhaled rsv therapeutic Large unmet need for rsv-specific treatment targeting infants presenting as out-patients 1 ...]]> Thu, 31 May 2012 22:00:00 +0000 http://www.reportlinker.com/d012927680/Pharmaceutical-Sector-Analysis-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d012927680/Pharmaceutical-Sector-Analysis-in-The-United-States.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... That pre-exist before therapy and can be selected by antiviral agents Pre-existing resistance associated variants present at baseline are not predictive of outcome (svr) While svr was achieved in many ...]]> Wed, 29 Feb 2012 23:00:00 +0000